Answer
No. People receiving terminal-complement inhibitors remain at increased risk of invasive meningococcal disease even if antibodies develop after vaccination.
Sources for this answer
- Nimenrix powder and solvent for solution for injection in pre-filled syringeemc · SmPC Current selected SmPC · Version 34